About Forest Laboratories (NYSE:FRX)
Forest Laboratories, Inc. (Forest), develops, manufactures and sells branded forms of ethical drug products, which requires a physician's prescription. The Company's products include Namenda, a N-methyl-D-aspartate (NMDA) antagonist for the treatment of moderate to severe dementia of the Alzheimer's type; Bystolic, a beta-blocker for the treatment of hypertension; Linzess, a guanylate cyclase type-C receptor agonist for the once-daily treatment for men and women suffering from IBS-C or CIC; Tudorza, a long-acting antimuscarinic agent for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and Viibryd, a SSRI and a 5-HT1A receptor partial agonist for the treatment of adults with depressive disorder (MDD). In February 2014, it acquired Aptalis. Effective July 2, 2014 Forest Laboratories Inc, a unit of Actavis PLC, acquired the entire share capital of Furiex Pharmaceuticals Inc.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
SymbolNYSE:FRX
CUSIP34583810
Phone+1-212-4217850
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Forest Laboratories (NYSE:FRX) Frequently Asked Questions
What is Forest Laboratories' stock symbol?
Forest Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "FRX."
Has Forest Laboratories been receiving favorable news coverage?
News headlines about FRX stock have trended somewhat positive on Tuesday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Forest Laboratories earned a news sentiment score of 0.13 on Accern's scale. They also assigned news coverage about the healthcare company an impact score of 49.30 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of Forest Laboratories?
Shares of FRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Forest Laboratories?
Forest Laboratories' mailing address is 909 3rd Ave, NEW YORK, NY 10022-4731, United States. The healthcare company can be reached via phone at +1-212-4217850.
MarketBeat Community Rating for Forest Laboratories (FRX)
MarketBeat's community ratings are surveys of what our community members think about Forest Laboratories and other stocks. Vote "Outperform" if you believe FRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Forest Laboratories (NYSE:FRX) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
(Data available from 4/24/2016 forward)
Forest Laboratories (NYSE:FRX) Earnings History and Estimates Chart
Forest Laboratories (NYSE FRX) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 4/29/2014 | Q414 | $0.45 | $0.87 | $959.00 million | $1.05 million | View | N/A |  |
| 1/21/2014 | Q314 | $0.06 | $0.27 | $827.25 million | $846.80 million | View | N/A | |
| 10/22/2013 | Q2 2014 | $0.14 | $0.36 | $828.99 million | $855.26 million | View | N/A | |
| 7/23/2013 | Q1 2014 | $0.09 | $0.28 | $798.41 million | $796.90 million | View | N/A | |
| 4/23/2013 | Q4 2013 | $0.16 | $0.17 | $807.00 million | $783.20 million | View | N/A | |
| 1/15/2013 | Q3 2013 | ($0.14) | ($0.21) | $765.94 million | $678.00 million | View | N/A | |
| 10/16/2012 | | $0.02 | $0.08 | | | View | N/A | |
| 7/17/2012 | | $0.24 | $0.28 | | | View | N/A | |
| 4/17/2012 | | $0.70 | $0.78 | | | View | N/A | |
| 1/17/2012 | | $1.01 | $1.04 | | | View | N/A | |
| 10/18/2011 | | $0.99 | $0.91 | | | View | N/A | |
| 7/19/2011 | | $0.97 | $1.04 | | | View | N/A | |
| 4/19/2011 | | $1.07 | $1.12 | | | View | N/A | |
| 1/18/2011 | | $0.99 | $1.34 | | | View | N/A | |
| 10/19/2010 | Q2 2011 | $0.94 | $1.00 | | | View | N/A | |
| 7/20/2010 | Q1 2011 | $0.86 | $0.95 | | | View | N/A | |
| 4/20/2010 | Q4 2010 | $0.83 | $0.83 | | | View | N/A | |
| 1/19/2010 | Q3 2010 | $0.86 | $0.97 | | | View | N/A | |
| 10/20/2009 | Q2 2010 | $0.85 | $0.86 | | | View | N/A | |
| 7/21/2009 | Q1 2010 | $0.82 | $0.87 | | | View | N/A | |
| 4/21/2009 | Q4 2009 | $0.75 | $0.76 | | | View | N/A | |
| 1/20/2009 | Q3 2009 | $0.76 | $1.03 | | | View | N/A | |
| 10/21/2008 | Q2 2009 | $0.69 | $0.80 | | | View | N/A | |
| 7/22/2008 | Q1 2009 | $0.80 | $0.87 | | | View | N/A | |
| 4/15/2008 | Q4 2008 | $0.77 | $0.90 | | | View | N/A | |
| 1/15/2008 | Q3 2008 | $0.75 | $0.96 | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Forest Laboratories (NYSE:FRX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Forest Laboratories (NYSE FRX) Insider Trading and Institutional Ownership History
Forest Laboratories (NYSE FRX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/27/2014 | Howard Solomon | Director | Sell | 250,000 | $65.41 | $16,352,500.00 | 464,881 | |
| 1/23/2014 | Howard Solomon | Director | Sell | 250,000 | $67.13 | $16,782,500.00 | 714,881 | |
| 1/22/2014 | Jerome Lynch | SVP | Sell | 135,625 | $67.28 | $9,124,850.00 | 66,577 | |
| 8/26/2013 | Lawrence Olanoff | Director | Sell | 1,104 | $42.96 | $47,427.84 | 91,354 | |
| 8/21/2013 | Perier Francis, Jr. | CFO | Sell | 12,000 | $43.00 | $516,000.00 | 99,439 | |
| 9/4/2012 | Carl C Icahn | Major Shareholder | Buy | 86,848 | $34.64 | $3,008,414.72 | | |
| 8/29/2012 | Carl C Icahn | Major Shareholder | Buy | 331,406 | $34.65 | $11,483,217.90 | | |
| 8/24/2012 | Carl C Icahn | Major Shareholder | Buy | 1,343,837 | $34.57 | $46,456,445.09 | | |
| 8/21/2012 | Carl C Icahn | Major Shareholder | Buy | 1,962,011 | $34.18 | $67,061,535.98 | | |
(Data available from 1/1/2013 forward)
Forest Laboratories (NYSE FRX) News Headlines
| Source: |
|
Forest Laboratories (NYSE:FRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Forest Laboratories (NYSE:FRX) Income Statement, Balance Sheet and Cash Flow Statement
Forest Laboratories (NYSE FRX) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
